Works matching AU Komrokji, Rami S.

Results: 111
    1

    Diagnostic and molecular testing patterns in patients with newly diagnosed acutemyeloid leukemia in the Connect® MDS/AML Disease Registry.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.16
    By:
    • Pollyea, Daniel A.;
    • George, Tracy I.;
    • Abedi, Mehrdad;
    • Bejar, Rafael;
    • Cogle, Christopher R.;
    • Foucar, Kathryn;
    • Garcia-Manero, Guillermo;
    • Grinblatt, David L.;
    • Komrokji, Rami S.;
    • Maciejewski, Jaroslaw P.;
    • Revicki, Dennis A.;
    • Roboz, Gail J.;
    • Savona, Michael R.;
    • Scott, Bart L.;
    • Sekeres, Mikkael A.;
    • Thompson, Michael A.;
    • Kurtin, Sandra E.;
    • Louis, Chrystal U.;
    • Nifenecker, Melissa;
    • Flick, E. Dawn
    Publication type:
    Article
    2

    Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.

    Published in:
    Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 27, doi. 10.3390/jcm11010027
    By:
    • Oliva, Esther Natalie;
    • Platzbecker, Uwe;
    • Garcia-Manero, Guillermo;
    • Mufti, Ghulam J.;
    • Santini, Valeria;
    • Sekeres, Mikkael A.;
    • Komrokji, Rami S.;
    • Shetty, Jeevan K.;
    • Tang, Derek;
    • Guo, Shien;
    • Liao, Weiqin;
    • Zhang, George;
    • Ha, Xianwei;
    • Ito, Rodrigo;
    • Lord-Bessen, Jennifer;
    • Backstrom, Jay T.;
    • Fenaux, Pierre
    Publication type:
    Article
    3
    4
    5
    6
    7

    Prospective CYP2C19‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.

    Published in:
    Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 563, doi. 10.1002/cpt.1641
    By:
    • Hicks, J. Kevin;
    • Quilitz, Rod E.;
    • Komrokji, Rami S.;
    • Kubal, Timothy E.;
    • Lancet, Jeffrey E.;
    • Pasikhova, Yanina;
    • Qin, Dahui;
    • So, Wonhee;
    • Caceres, Gisela;
    • Kelly, Kerry;
    • Salchert, Yasmina S.;
    • Shahbazian, Kevin;
    • Abbas‐Aghababazadeh, Farnoosh;
    • Fridley, Brooke L.;
    • Velez, Ana P.;
    • McLeod, Howard L.;
    • Greene, John N.
    Publication type:
    Article
    8
    9
    10
    11

    Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 1, p. E1, doi. 10.1002/ajh.25644
    By:
    • Mora, Barbara;
    • Guglielmelli, Paola;
    • Rumi, Elisa;
    • Maffioli, Margherita;
    • Barraco, Daniela;
    • Rambaldi, Alessandro;
    • Caramella, Marianna;
    • Komrokji, Rami S.;
    • Kiladjian, Jean‐Jacques;
    • Gotlib, Jason;
    • Iurlo, Alessandra;
    • Cervantes, Francisco;
    • Devos, Timothy;
    • Palandri, Francesca;
    • De Stefano, Valerio;
    • Ruggeri, Marco;
    • Silver, Richard T.;
    • Albano, Francesco;
    • Benevolo, Giulia;
    • Cavalloni, Chiara
    Publication type:
    Article
    12
    13
    14
    15

    Autoimmune diseases and myelodysplastic syndromes.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 5, p. E280, doi. 10.1002/ajh.24333
    By:
    • Komrokji, Rami S.;
    • Kulasekararaj, Austin;
    • Al Ali, Najla H.;
    • Kordasti, Shahram;
    • Bart-Smith, Emily;
    • Craig, Benjamin M.;
    • Padron, Eric;
    • Zhang, Ling;
    • Lancet, Jeffrey E.;
    • Pinilla-Ibarz, Javier;
    • List, Alan F.;
    • Mufti, Ghulam J.;
    • Epling-Burnette, Pearlie K.
    Publication type:
    Article
    16
    17
    18

    A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 9, p. E156, doi. 10.1002/ajh.23780
    By:
    • Garcia-Manero, Guillermo;
    • Gartenberg, Gary;
    • Steensma, David P.;
    • Schipperus, Martin R.;
    • Breems, Dimitri A.;
    • Paz, Raquel;
    • Valcárcel, David;
    • Kranenburg, Britte;
    • Reddy, Manjula;
    • Komrokji, Rami S.
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25

    Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

    Published in:
    Cancer Medicine, 2016, v. 5, n. 7, p. 1694, doi. 10.1002/cam4.721
    By:
    • Rollison, Dana E.;
    • Shain, Kenneth H.;
    • Lee, Ji‐Hyun;
    • Hampras, Shalaka S.;
    • Fulp, William;
    • Fisher, Kate;
    • Al Ali, Najla H.;
    • Padron, Eric;
    • Lancet, Jeffrey;
    • Xu, Qiang;
    • Olesnyckyj, Martha;
    • Kenvin, Laurie;
    • Knight, Robert;
    • Dalton, William;
    • List, Alan;
    • Komrokji, Rami S.
    Publication type:
    Article
    26
    27

    Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.

    Published in:
    2021
    By:
    • Kanagal-Shamanna, Rashmi;
    • Montalban-Bravo, Guillermo;
    • Katsonis, Panagiotis;
    • Sasaki, Koji;
    • Class, Caleb A.;
    • Jabbour, Elias;
    • Sallman, David;
    • Hunter, Anthony Michael;
    • Benton, Christopher;
    • Chien, Kelly S.;
    • Luthra, Rajyalakshmi;
    • Bueso-Ramos, Carlos E.;
    • Kadia, Tapan;
    • Andreeff, Michael;
    • Komrokji, Rami S.;
    • Al Ali, Najla H;
    • Short, Nicholas;
    • Daver, Naval;
    • Routbort, Mark J.;
    • Khoury, Joseph D.
    Publication type:
    Letter to the Editor
    28
    29

    Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 7, p. 3576, doi. 10.1007/s12325-025-03208-5
    By:
    • Garcia-Manero, Guillermo;
    • Santini, Valeria;
    • Zeidan, Amer M.;
    • Komrokji, Rami S.;
    • Pozharskaya, Veronika;
    • Rose, Shelonitda;
    • Keeperman, Karen;
    • Lai, Yinzhi;
    • Kalsekar, Sameer;
    • Aggarwal, Barkha;
    • Miteva, Dimana;
    • Valcárcel, David;
    • Fenaux, Pierre;
    • Shortt, Jake;
    • Della Porta, Matteo Giovanni;
    • Platzbecker, Uwe
    Publication type:
    Article
    30

    The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

    Published in:
    BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10073-w
    By:
    • Moyo, Tamara K.;
    • Mendler, Jason H.;
    • Itzykson, Raphael;
    • Kishtagari, Ashwin;
    • Solary, Eric;
    • Seegmiller, Adam C.;
    • Gerds, Aaron T.;
    • Ayers, Gregory D.;
    • Dezern, Amy E.;
    • Nazha, Aziz;
    • Valent, Peter;
    • van de Loosdrecht, Arjan A.;
    • Onida, Francesco;
    • Pleyer, Lisa;
    • Cirici, Blanca Xicoy;
    • Tibes, Raoul;
    • Geissler, Klaus;
    • Komrokji, Rami S.;
    • Zhang, Jing;
    • Germing, Ulrich
    Publication type:
    Article
    31

    The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

    Published in:
    2022
    By:
    • Moyo, Tamara K.;
    • Mendler, Jason H.;
    • Itzykson, Raphael;
    • Kishtagari, Ashwin;
    • Solary, Eric;
    • Seegmiller, Adam C.;
    • Gerds, Aaron T.;
    • Ayers, Gregory D.;
    • Dezern, Amy E.;
    • Nazha, Aziz;
    • Valent, Peter;
    • van de Loosdrecht, Arjan A.;
    • Onida, Francesco;
    • Pleyer, Lisa;
    • Cirici, Blanca Xicoy;
    • Tibes, Raoul;
    • Geissler, Klaus;
    • Komrokji, Rami S.;
    • Zhang, Jing;
    • Germing, Ulrich
    Publication type:
    journal article
    32
    33

    PB2225: A RANDOMIZED OPEN‐LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE‐2 OR HIGH‐RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000975644.99899.f4
    By:
    • Mascarenhas, John;
    • Harrison, Claire;
    • Kiladjian, Jean‐Jacques;
    • Sockel, Katja;
    • Vannucchi, Alessandro;
    • Berry, Tymara;
    • Redding, Denise;
    • Sherman, Laurie;
    • Dougherty, Souria;
    • Peng, Lixian;
    • Sun, Libo;
    • Huang, Fei;
    • Wan, Ying;
    • Rodolf, Vivian;
    • Ho, Judy;
    • Navada, Shyamala;
    • Komrokji, Rami S.
    Publication type:
    Article
    34

    PB2221: AN OPEN‐LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000975628.90605.7e
    By:
    • Kuykendall, Andrew;
    • Bradley, Terrence;
    • Komrokji, Rami S.;
    • Berry, Tymara;
    • Dougherty, Souria;
    • Sherman, Laurie;
    • Peng, Lixian;
    • Huang, Fei;
    • Wan, Ying;
    • Rodolf, Vivian;
    • Ho, Judy;
    • Navada, Shyamala;
    • Mascarenhas, John
    Publication type:
    Article
    35
    36
    37

    P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000969832.59030.29
    By:
    • Sekeres, Mikkael;
    • Santini, Valeria;
    • Díez Campelo, María;
    • S. Komrokji, Rami;
    • Fenaux, Pierre;
    • Robert Savona, Michael;
    • Madanat, Yazan;
    • Valcárcel, David;
    • Illmer, Thomas;
    • Jonášová, Anna;
    • Belohlavkova, Petra;
    • Regnault, Antoine;
    • Creel, Kristin;
    • Sengupta, Nishan;
    • Sherman, Laurie;
    • Berry, Tymara;
    • Dougherty, Souria;
    • Shah, Sheetal;
    • Sun, Libo;
    • Wan, Ying
    Publication type:
    Article
    38
    39

    S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967592.61626.0d
    By:
    • Komrokji, Rami S.;
    • Ball, Somdeb;
    • Maggioni, Giulia;
    • Travaglino, Erica;
    • Al Ali, Najla;
    • Fenaux, Pierre;
    • Platzbecker, Uwe;
    • Santini, Valeria;
    • Díez Campelo, María;
    • Haferlach, Torsten;
    • Singh, Avani;
    • Jain, Akriti;
    • Aguirre, Luis E.;
    • Tinsley, Sara;
    • Schwabkey, Zaker;
    • Chan, Onyee;
    • Xie, Zhuoer;
    • Brunner, Andrew;
    • Kuykendall, Andrew;
    • Bennett, John
    Publication type:
    Article
    40

    S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE‐536‐MF‐001 STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967580.08826.11
    By:
    • Gerds, Aaron T.;
    • Harrison, Claire;
    • Kiladjian, Jean‐Jacques;
    • Mesa, Ruben;
    • Vannucchi, Alessandro;
    • Komrokji, Rami S.;
    • Bose, Prithviraj;
    • Kremyanskaya, Marina;
    • Mead, Adam;
    • Gotlib, Jason;
    • Sanabria, Fabian;
    • Marsousi, Niloufar;
    • Giuseppi, Ana Carolina;
    • Jiang, Huijing;
    • Palmer, Jeanne;
    • Mccaul, Kelly;
    • Ribrag, Vincent;
    • Verstovsek, Srdan;
    • Passamonti, Francesco
    Publication type:
    Article
    41

    S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA‐NAIVE LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967316.99954.0c
    By:
    • Della Porta, Matteo Giovanni;
    • Platzbecker, Uwe;
    • Santini, Valeria;
    • Zeidan, Amer M.;
    • Fenaux, Pierre;
    • Komrokji, Rami S.;
    • Shortt, Jake;
    • Valcárcel, David;
    • Jonášová, Anna;
    • Dimicoli‐Salazar, Sophie;
    • Tiong, Ing Soo;
    • Lin, Chien‐Chin;
    • LI, Jiahui;
    • Zhang, Jennie;
    • Carolina Giuseppi, Ana;
    • Kreitz, Sandra;
    • Pozharskaya, Veronika;
    • Keeperman, Karen L.;
    • Rose, Shelonitda;
    • Shetty, Jeevan K.
    Publication type:
    Article
    42
    43

    Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study.

    Published in:
    2025
    By:
    • Sekeres, Mikkael A.;
    • Santini, Valeria;
    • Díez-Campelo, Maria;
    • Komrokji, Rami S.;
    • Fenaux, Pierre;
    • Savona, Michael R.;
    • Madanat, Yazan F.;
    • Valcárcel-Ferreiras, David;
    • Oliva, Esther Natalie;
    • Regnault, Antoine;
    • Creel, Kristin;
    • Sengupta, Nishan;
    • Dougherty, Souria;
    • Shah, Sheetal;
    • Sun, Libo;
    • Wan, Ying;
    • Navada, Shyamala;
    • Zeidan, Amer M.;
    • Platzbecker, Uwe
    Publication type:
    Letter to the Editor
    44
    45
    46

    The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

    Published in:
    Leukemia & Lymphoma, 2019, v. 60, n. 13, p. 3161, doi. 10.1080/10428194.2019.1616186
    By:
    • Sekeres, Mikkael A.;
    • Gore, Steven D.;
    • Stablein, Donald M.;
    • DiFronzo, Nancy;
    • Abel, Gregory A.;
    • DeZern, Amy E.;
    • Troy, Jesse D.;
    • Rollison, Dana E.;
    • Thomas, John W.;
    • Waclawiw, Myron A.;
    • Liu, Jane Jijun;
    • Al Baghdadi, Tareq;
    • Walter, Matthew J.;
    • Bejar, Rafael;
    • Gorak, Edward J.;
    • Starczynowski, Daniel T.;
    • Foran, James M.;
    • Cerhan, James R.;
    • Moscinski, Lynn C.;
    • Komrokji, Rami S.
    Publication type:
    Article
    47

    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

    Published in:
    Leukemia & Lymphoma, 2019, v. 60, n. 1, p. 246, doi. 10.1080/10428194.2018.1468893
    By:
    • Stahl, Maximilian;
    • DeVeaux, Michelle;
    • Montesinos, Pau;
    • Itzykson, Raphaël;
    • Ritchie, Ellen K.;
    • Sekeres, Mikkael A.;
    • Barnard, John;
    • Podoltsev, Nikolai A.;
    • Brunner, Andrew;
    • Komrokji, Rami S.;
    • Bhatt, Vijaya R.;
    • Al-Kali, Aref;
    • Cluzeau, Thomas;
    • Santini, Valeria;
    • Roboz, Gail J.;
    • Fenaux, Pierre;
    • Litzow, Mark;
    • Fathi, Amir T.;
    • Perreault, Sarah;
    • Kim, Tae Kon
    Publication type:
    Article
    48
    49

    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 7, p. 1672, doi. 10.1080/10428194.2017.1397663
    By:
    • Strati, Paolo;
    • Tang, Guilin;
    • Duose, Dzifa Y.;
    • Mallampati, Saradhi;
    • Luthra, Rajyalakshmi;
    • Patel, Keyur P.;
    • Hussaini, Mohammad;
    • Mirza, Abu-Sayeef;
    • Komrokji, Rami S.;
    • Oh, Stephen;
    • Mascarenhas, John;
    • Najfeld, Vesna;
    • Subbiah, Vivek;
    • Kantarjian, Hagop;
    • Garcia-Manero, Guillermo;
    • Verstovsek, Srdan;
    • Daver, Naval
    Publication type:
    Article
    50